Michael J. Powell, Ph.D.
Title: Chief Scientific Officer, DiaCarta, Inc.
Mike Powell Ph.D. is a highly recognized scientific and business leader with more than 25 year’s experience in R&D, technology, business and corporate development. Dr. Powell has held R&D Director positions at Roche, Microgenics and was a pioneer and lead scientist and inventor of the electrochemiluminescence (ECL) assay technology and also developed catalytic antibodies at IGEN, Inc. which was acquired by Roche for $1.4B in 2003. Mike has held several other R & D senior management positions at Integrated Genetics Inc., Medisense and Celltech PLC, in the UK. Medisense was acquired by Abbott in 1996 for $876M and Celltech was acquired by UCB Pharma in 2004 for $1.5B Euro. Mike brings expertise In the fields of molecular diagnostic assay research and development, qPCR and other nucleic acid amplification technologies, and automated instrumentation platforms to DiaCarta.